Abstract
The antibody-dependent cell-mediated cytotoxicity (ADCC) of the anti-CD20 monoclonal antibodies (mAbs) rituximab and obinutuzumab against the cell line Raji and isolated CLL cells and its potential impairment by kinase inhibitors (KI) was determined via lactate dehydrogenase release or calcein retention, respectively, using genetically modified NK92 cells expressing CD16-176V as effector cells. Compared to peripheral blood mononuclear cells, recombinant effector cell lines showed substantial alloreactivity-related cytotoxicity without addition of mAbs but afforded determination of ADCC with reduced interassay variability. The cytotoxicity owing to alloreactivity was less susceptible to interference by KI than the ADCC of anti-CD20 mAbs, which was markedly diminished by ibrutinib, but not by idelalisib. Compared to rituximab, the ADCC of obinutuzumab against primary CLL cells showed approximately 30% higher efficacy and less interference with KI. Irreversible BTK inhibitors at a clinically relevant concentration of 1 μM only weakly impaired the ADCC of anti-CD20 mAbs, with less influence in combinations with obinutuzumab than with rituximab and by acalabrutinib than by ibrutinib or tirabrutinib. In summary, NK cell line-based as...Continue Reading
References
Oct 9, 2004·The Journal of Biological Chemistry·Lillian S ShahiedLouis M Weiner
Apr 22, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Liat BinyaminLouis M Weiner
Mar 3, 2010·Blood·Ekkehard MössnerPablo Umaña
Jun 5, 2010·Blood·Sarah E M HermanAmy J Johnson
Oct 5, 2010·Lancet·M HallekUNKNOWN German Chronic Lymphocytic Leukaemia Study Group
Dec 16, 2010·British Journal of Haematology·Michaela PatzGünter Krause
May 17, 2011·Molecular Immunology·Alfred SchnuerigerMarcel Zocher
Mar 6, 2012·Archives of Biochemistry and Biophysics·Josée Golay, Martino Introna
Sep 26, 2012·The Journal of Clinical Investigation·Jennifer T GrierJordan S Orange
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Jul 23, 2013·Molecular Cancer Therapeutics·Sylvia HerterChristian Klein
Sep 26, 2013·Blood·Michael Hallek
Jan 10, 2014·The New England Journal of Medicine·Valentin GoedeMichael Hallek
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
Feb 4, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sylvia HerterMarina Bacac
Feb 5, 2014·Leukemia·K BojarczukM Winiarska
Mar 22, 2014·Blood·Holbrook E KohrtJohn C Byrd
Apr 8, 2014·Journal of Immunological Methods·Shan ChungAn Song
Oct 26, 2014·Haematologica·Fabio Da RoitJosée Golay
Dec 20, 2014·MAbs·Minh Ngoc DuongCharles Dumontet
Apr 29, 2015·International Journal of Cancer. Journal International Du Cancer·Elisa GöckeritzGünter Krause
Sep 30, 2016·Leukemia & Lymphoma·Tomoko YasuhiroToshio Yoshizawa
Jun 24, 2017·Haematologica·Josée GolayMartino Introna
Citations
Apr 12, 2019·Frontiers in Immunology·Amandine PradierJörg D Seebach
Aug 23, 2020·Cancers·Verena BarbarinoChristian P Pallasch
Jan 10, 2020·Cancer Discovery·Jennifer A WoyachJohn C Byrd
Mar 29, 2021·Virology·Xuemin ChenEvan J Anderson
Jun 24, 2018·Antibody Therapeutics·David ZahaviLouis M Weiner